Michael O’Shea: Safety of DOACs Versus Warfarin in Adults with Congenital Heart Disease
Michael O’Shea, Assistant Professor and Instructor of Medicine at Mayo Clinic Alix School of Medicine, shared a post on X about a recent article he and his colleagues co-authored, published in Heart Rhythm O2, adding:
‘How safe are DOACs in Tetralogy of Fallot and PA-IVS?
We found ~5× higher bleeding with DOACs vs warfarin, particularly in patients with worse RV function.”
Title: Atrial Arrhythmia and Anticoagulant Risks in Tetralogy of Fallot and Pulmonary Atresia with Intact Ventricular Septum
Authors: Michael O’Shea, Suganya Karikalan, Srekar Ravi, Matthew Van Ligten, Adam Bacon, Eiad Habib, Omar Baqal, Philip Smyth, Winston Wang, Dani Green, Nneoma Alozie, Chelsea Marshal, Alexander Egbe, Heidi Connolly, Marlene Girardo, Abhishek Deshmukh, Hicham El Masry, David Majdalany
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 23, 2026, 06:43Tim Blair: Improving DVT Awareness, Early Diagnosis, and Access to Treatment
-
Oct 22, 2026, 18:04Basem Goueli: Blood Clots in the NFL
-
Oct 22, 2026, 17:57Syed Ahmed: Viral Triggers of Immune Thrombocytopenia and Thrombosis
-
Oct 22, 2026, 17:49Valerie Tutwiler: Bridging Engineering and Medicine to Advance Thrombosis Research
-
Oct 22, 2026, 17:41Jesus Ardila Novoa: How Patient Education Can Transform Hemophilia Care
-
Oct 22, 2026, 17:30Filipe Gonçalves: Advancing Bleeding Disorder Diagnosis Through Multidisciplinary Collaboration
-
Oct 22, 2026, 17:17Storage Pool Deficiency An Overview of a Rare Platelet Disorder – EHC
-
Oct 22, 2026, 17:10Matthew Hazell: Optimizing the Use of Rare Red Blood Cell Units
-
Oct 22, 2026, 17:03Smita Patil: New Insights Into Platelet Alpha-Granule Secretion